GlassScriptPhysician profile
Guity Farahmand
NPI 1700017175
$5,942.45
in general payments reported to CMS, 2019-2025
25 companies · $2,186 in 2025
The $2,186 reported for 2025 was more than what 90% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.73 · 2020: $161 · 2021: $300 · 2022: $347 · 2023: $1,350 · 2024: $1,505 · 2025: $2,186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,878 · Education: $144 · Travel and Lodging: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,877.62 |
| Education | $144.27 |
| Travel and Lodging | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $778.77 | 2022-2025 | Velphoro, Velphoro, Korsuva |
| Astrazeneca Pharmaceuticals LP | $741.71 | 2019-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $644.29 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $602.64 | 2020-2025 | Jynarque, Voyxact |
| Novo Nordisk INC | $474.44 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $415.12 | 2022-2025 | Krystexxa, Tavneos |
| Calliditas Therapeutics US INC. | $293.83 | 2022-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $236.71 | 2023-2025 | |
| Vifor Pharma, INC. | $235.68 | 2019-2025 | Veltassa, Korsuva |
| Horizon Therapeutics Plc | $228.61 | 2022-2023 | Krystexxa |
| Lilly USA, LLC | $183.09 | 2024-2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $176.23 | 2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.40 | 2023-2025 | Jardiance |
| Opko Pharmaceuticals, LLC | $139.71 | 2022-2025 | Rayaldee |
| Daiichi Sankyo INC. | $125.47 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $118.82 | 2025 | Acthar |
| Ardelyx, INC. | $97.16 | 2023-2024 | Ibsrela |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $74.78 | 2023-2024 | Jynarque |
| Glaxosmithkline, LLC. | $53.41 | 2023-2024 | Jesduvroq, Benlysta |
| Novartis Pharmaceuticals Corporation | $45.07 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $29.25 | 2023 | Lupkynis |
| Apellis Pharmaceuticals, INC. | $26.72 | 2025 | Empaveli |
| Scpharmaceuticals INC. | $25.02 | 2025 | |
| Janssen Pharmaceuticals, INC | $22.03 | 2019 | |
| Veloxis Pharmaceuticals, INC. | $16.49 | 2024 | Envarsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guity Farahmand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.